Literature DB >> 14707443

Expression of cyclooxygenase-1 and cyclooxygenase-2 in human esophageal mucosa, dysplasia and carcinoma.

Satoru Kase1, Mitsuhiko Osaki, Soichiro Honjo, Kiyoshi Hashimoto, Hironobu Adachi, Shunichi Tsujitani, Hisao Ito.   

Abstract

OBJECTIVE: COX (cyclooxygenase), a prostaglandin H synthase, catalyzes the rate-limiting step in prostaglandin biosynthesis. Two isoforms of COX have been identified: COX-1 and COX-2. We examined the expression of COX-1 and COX-2 in esophageal normal mucosa, dysplasia and squamous cell carcinoma (SCC).
METHODS: The expression of COX-1 and COX-2 in 80 surgically removed esophagi due to SCC, as well as in 5 human esophageal SCC cell lines was analyzed, using immunohistochemistry and Western blot analyses.
RESULTS: COX-1 and COX-2 were variably expressed in the SCC cell lines. Higher COX-1 expression was noted in 31 (41.9%) of the 74 specimens of normal mucosa, in none of the 40 specimens of dysplastic mucosa and in 15 (18.8%) of the 80 specimens of SCC, the frequency being significantly higher in normal mucosa than in dysplasia or SCC (p < 0.0001, p = 0.0018, respectively). COX-1 expression was significantly higher in well-differentiated SCC than in moderately or poorly differentiated SCC (p < 0.01). Higher COX-2 expression was noted in none (0.0%) of the specimens of normal mucosa, in 12 (30%) of the specimens of dysplastic mucosa, and in 41 (51.3%) of the speciments of SCC, the frequency being significantly higher in SCC than in normal mucosa or dysplasia (p < 0.0001, p = 0.0278, respectively).
CONCLUSIONS: COX-1 is expressed in normal esophageal mucosa and is occasionally induced in well-differentiated SCC, whereas COX-2 expression is more characteristic of dysplasia and carcinoma than of normal mucosa, implying a possible association with cell differentiation in the former, and esophageal tumorigenesis in the latter. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14707443     DOI: 10.1159/000074421

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  5 in total

1.  Erythropoietin in thyroid cancer.

Authors:  C M Yates; A Patel; K Oakley; A Helms; R M Tuttle; G L Francis
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 4.256

2.  Effects of the inhibition of cyclooxygenase-2 on human esophageal cancer cells: inhibition of cell proliferation and induction of apoptosis.

Authors:  Li Zhang; Jun Tu; Zhong-Lin Yu; Yong-Dong Wu; Cai-Min Xu; Shu-Tian Zhang
Journal:  Pathol Oncol Res       Date:  2009-07-25       Impact factor: 3.201

Review 3.  The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis.

Authors:  Zaoxiu Hu; Yanlong Yang; Yonghe Zhao; Yunchao Huang
Journal:  Onco Targets Ther       Date:  2017-06-09       Impact factor: 4.147

4.  Cyclooxygenase-2, a Potential Therapeutic Target, Is Regulated by miR-101 in Esophageal Squamous Cell Carcinoma.

Authors:  Ying Shao; Peng Li; Sheng-tao Zhu; Ji-ping Yue; Xiao-jun Ji; Zhen He; Dan Ma; Li Wang; Yong-jun Wang; Ye Zong; Yong-dong Wu; Shu-tian Zhang
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

5.  MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.

Authors:  Ying Shao; Peng Li; Sheng-Tao Zhu; Ji-Ping Yue; Xiao-Jun Ji; Dan Ma; Li Wang; Yong-Jun Wang; Ye Zong; Yong-Dong Wu; Shu-Tian Zhang
Journal:  Oncotarget       Date:  2016-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.